http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Anti-TNF-α 치료받은 강직성 척추염에서 체중 및 골밀도 변화
김태환 ( Tae Hwan Kim ),윤혜진 ( Hyae Jin Yun ) 대한내과학회 2013 대한내과학회지 Vol.85 No.5
Ankylosing spondylitis (AS) is a chronic inflammatory disorder primarily involving the sacroiliac joints and spine. It usually affects young people, and bone formation and resorption are implicated in the pathogenesis of AS. Non- steroidal anti-inflammatory drugs (NSAIDs) are the first line therapy and are very effective in most of patients who have inflammatory back pain. If NSAIDs are not effective, anti-TNF-α agents are strongly recommended in severe inflammatory back pain. Anti-TNF-α is very effective in most of AS patients. A study by Lee et al. showed that AS patients who were treated with anti-TNF-α have weight gain and improvement of osteoporosis. In this editorial, studies on the improvement of weight and osteoporosis with anti-TNF-α agents are reviewed. (Korean J Med 2013;85:485-488)
이현주,노종현,양버들,우경완,송용진,이에나,이융재,황태연,김선라,조현우,정용현,이무진 한국생약학회 2020 생약학회지 Vol.51 No.4
Lentinus edodes (LE) is the first medicinal macrofungus to enter the realm of modern biotechnology. Lentinus edodes is well-known to have anti-tumor, anti-inflammatory, and immunomodulatory effects. In this study, osteoporosis was induced by ovariectomy in female rats, and the prevention and treatment efficacy of the climacteric disease the postmenopausal type I pattern was examined using the experimental substance. Female rats were either sham-operated (sham; n = 5) or surgically ovariectomized (OVX; five animals per group) and then administered to OVX control, raloxifene hydrochloride 1 mg/kg/day, or LE (20 and 200 mg/kg/day) for 12 weeks. LE treatment suppressed the ovariectomy-induced reduction of bone mineral density in the entire tibia as well as its metaphysis with a decrease of serum osteocalcin and interleukin-6 levels. In addition, LE is suggested to elevate the serum levels of progesterone hormones and prevent bone loss in ovariectomized rats. In conclusion, LE 200 mg/kg/day may have inhibitory effects on osteoporosis in OVX rats.
Access to Anti-osteoporosis Medication after Hip Fracture in Korean Elderly Patients
Yu, Y.M.,Lee, J.Y.,Lee, E. Elsevier/North-Holland Biomedical Press 2017 Maturitas Vol.103 No.-
Purpose: This study aims to evaluate access to anti-osteoporosis medication (AOM) and the factors affecting their prescription for Korean elderly patients with a hip fracture. Methods: A cross-sectional study was conducted on hip fracture patients aged 65 years or more using national-level data from 2013 to 2014. The prescription rates of AOM within 3 months after hip fracture were determined and the factors affecting AOM prescriptions were identified through multivariate logistic regression. Results: A total of 6307 elderly patients were selected from a national medical insurance database, giving an estimated 15,768 patients nationally in a nine-month period. One-third of the patients (33.5%) received an AOM prescription and only 9.4% of the patients were prescribed an AOM with calcium and vitamin D supplements. Being 80 years and older (adjusted OR, 0.78; 95% CI, 0.70-0.88) and having three or more comorbid diseases (adjusted OR, 0.66; 95% CI, 0.55-0.78) were associated with a lower likelihood of an AOM prescription. Female sex (adjusted OR, 2.54; 95% CI, 2.17-2.98), an osteoporosis diagnosis (adjusted OR, 2.50; 95% CI, 2.15-2.91), concurrent thiazolidinedione therapy (adjusted OR, 2.11; 95% CI, 1.29-3.45) and a dual-energy X-ray absorptiometry (DXA) examination after hip fracture (adjusted OR 4.11; 95% CI, 3.67-4.62) were all significant predictive factors for AOM prescription. Bisphosphonates were the most frequently prescribed AOMs (92.2%). Conclusions: The AOM prescription rate for elderly patients with hip fractures was suboptimal in Korea. Factors affecting an AOM prescription were age, sex, clinical comorbidity, osteoporosis status, concurrent thiazolidinedione therapy, and receiving a DXA examination after hip fracture.
Bui Thi Thuy Luyen,BUIHUU TAI,Nguyen Phuong Thao,이상현,장해동,이영미,김영호 한국응용생명화학회 2014 Applied Biological Chemistry (Appl Biol Chem) Vol.57 No.5
Antioxidant and anti-osteoporosis activities of extractsand chemical constituents from the whole plant of Euphorbiamaculata were investigated. The MeOH extract, as well as EtOAcand H2O fractions (10.0 μg/mL), exhibited potent antioxidantactivities. Their oxygen radical absorbance capacity and cupricion reducing antioxidant capacity values were 27.07±0.31 to28.47±0.36 and 43.86±0.26 to 46.67±0.34 fold higher than thoseof 1.0 μM Trolox, respectively. The MeOH extract and EtOAcfraction (at 10.0 μg/mL) also significantly suppressed excessivebone resorption by osteoclasts with tartrate-resistant acid phosphatase(TRAP) activity values of 154.90±4.25 and 163.95±9.77%,respectively. Bioassay guided isolation of the EtOAc and H2Ofractions afforded 19 known compounds (1−19). Of these,compounds 18, and 13−15 showed good antioxidant activitybased on peroxyl radical-scavenging and reducing capacity assays,whereas compounds 1, 4, 7, and 14 showed the most significantinhibitory effect with TRAP activity values ranging from 121.31±1.41 to 110.00±3.74% relative to the control.
Synthesis and Anti-osteoporosis Potential of Two New Indirubin-3`-oxime Derivatives
( Nguyen Manh Cuong ),( Bui Huu Tai ),( Dang Hoang Hoan ),( Pham Quoc Long ),( Eun Mi Choi ),( Young Ho Kim ) 한국응용생명화학회 2010 Applied Biological Chemistry (Appl Biol Chem) Vol.53 No.1
Two new indirubin-3`-oxime derivatives, indirubin-3`-[O-(3-bromoprop-1-yl)-oxime] (2) and indirubin-3`-[O-(methoxycarbonylmethyl)-oxime] (3) were synthesized. Their structures were confirmed by ESI-MS and NMR spectroscopic method. Both of them (5 μg/mL) significantly caused a elevation of cell growth, alkaline phosphate activity, and mineralization in osteoblastic MC3T3-E1 cells (p<0.05).
( Dong Hyuk Sheen ),( Seung Jae Hong ),( Sang Heon Lee ),( Hye Soon Lee ),( Won Tae Chung ),( Hongsi Jiang ),( Sungmin Lee ),( Dae Hyun Yoo ) 대한류마티스학회 2019 대한류마티스학회지 Vol.26 No.1
Objective. Evaluate effectiveness/safety of tacrolimus in patients in Korea with active rheumatoid arthritis (RA) and unsuccessful response to disease-modifying anti-rheumatic drugs (DMARDs). Methods. Open-label, single-arm, non-comparative, 24-week, Phase-IV study in patients with active RA who had taken DMARDs for >6 months. Following a washout period, tacrolimus was initiated (baseline-12 weeks; dose 2 mg/day and 1.5 mg/day in patients aged ≤65 and >65 years, respectively). After 12 weeks, dose could be adjusted (remaining between 1~3 mg); treatment continued to 24 weeks. Primary endpoint was American College of Rheumatology 20% improvement (ACR20) (baseline-Week 24). Secondary endpoints included ACR50/ACR70 response, disease-activity score in 28 joints (DAS28) erythrocyte sedimentation rate (ESR), number of tender/ swollen joints, and bone mineral density (BMD) loss. Adverse events (AEs) were recorded. Results. Overall, 121 patients were analysed. Mean ±standard deviation tacrolimus dose baseline-Week 24 was 1.81±0.47 mg/day. After 24 weeks, 64.5%, 39.7%, and 19.0% of patients were ACR20, ACR50, and ACR70 responders, respectively. DAS28-ESR score decreased from 5.5±0.8 (baseline) to 3.7±1.5 (Week 24; p<0.0001); number of tender/swollen joints decreased. Between screening and Week 24, change in BMD-T score in lumbar and femur regions was -0.06±0.38 (p=0.1550) and -0.04±0.28 (p=0.0936), respectively, with no significant change in International Society for Clinical Densitometry classification. Fifty-six (46.3%) patients experienced 93 AEs; 75.3% were mild. No unexpected safety signals identified. Conclusion. Tacrolimus therapy was associated with a high proportion of ACR responders, and improved DAS28-ESR score and physical joint function during the study. Tacrolimus may be a suitable therapy for DMARD-resistant patients with RA. (J Rheum Dis 2019;26:20-30)
Synthesis and Anti-osteoporosis Potential of Two New Indirubin-3'-oxime Derivatives
Cuong, Nguyen Manh,Tai, Bui Huu,Hoan, Dang Hoang,Long, Pham Quoc,Choi, Eun-Mi,Kim, Young-Ho The Korean Society for Applied Biological Chemistr 2010 Applied Biological Chemistry (Appl Biol Chem) Vol.53 No.1
Two new indirubin-3'-oxime derivatives, indirubin-3'-[O-(3-bromoprop-1-yl)-oxime] (2) and indirubin-3'-[O-(methoxycarbonylmethyl)-oxime] (3) were synthesized. Their structures were confirmed by ESI-MS and NMR spectroscopic method. Both of them (5 ${\mu}g/mL$) significantly caused a elevation of cell growth, alkaline phosphate activity, and mineralization in osteoblastic MC3T3-E1 cells(p<0.05).
So-Young Choi,Dongsun Park,Goeun Yang,Sun Hee Lee,Dae Kwon Bae,Seock-Yeon Hwang,Paul K Lee,Yun-Bae Kim,Ill-Hwa Kim,Hyun-Gu Kang 한국실험동물학회 2011 Laboratory Animal Research Vol.27 No.4
This study was conducted to evaluate the effect of Sigma Anti-bonding Molecule Calcium Carbonate (SAC) as therapy for ovariectomy-induced osteoporosis in rats. Three weeks after surgery, fifteen ovariectomized Sprague-Dawley rats were divided randomly into 3 groups: sham-operated group (sham), ovariectomized group (OVX) and SAC-treatment group (OVX+SAC). The OVX+SAC group was given drinking water containing 0.0012% SAC for 12 weeks. Bone breaking force and mineralization as well as blood parameters related to the bone metabolism were analyzed. In OVX animals, blood concentration of 17β-estradiol decreased significantly, while osteocalcin and type I collagen C-terminal telopeptides (CTx) increased. Breaking force, bone mineral density (BMD), calcium and phosphorus in femurs, as well as uterine and vaginal weights, decreased significantly following OVX. However, SAC treatment (0.0012% in drinking water) not only remarkably restored the decreased 17β-estradiol and increased osteocalcin and CTx concentrations, but also recovered decreased femoral breaking force, BMD, calcium and phosphorus, although it did not reversed reproductive organ weights. It is suggested that SAC effectively improve bone density by preventing bone turnover mediated osteocalcin, CTx and minerals, and that it could be a potential candidate for therapy or prevention of postmenopausal osteoporosis.
Da Eun Lee,Kun Hee Park,Joo-Hyun Hong,Seon Hee Kim,Ki-Moon Park,Ki Hyun Kim 대한약학회 2023 Archives of Pharmacal Research Vol.46 No.9
In a previous study, we discovered that the ethanolic extract of sea buckthorn (Hippophae rhamnoides) fruits exhibited anti-osteoporosis effects both in vitro and in vivo. Through bioassay-guided fractionation, we identified the hexane fraction (HRH) as the active fraction, which was further fractionated using preparative HPLC. Among the resulting six fractions, HRHF4 showed significant activity. In the present study, we focused on the bioassay-guided isolation of bioactive compounds from the HRHF4 fraction. We successfully identified the active HRHF43 fraction, which led us to the isolation of potential bioactive compounds (1–6). The chemical structures of these compounds were determined using NMR data, LC-MS analysis, and HR-ESI-MS data as four triterpenes, ursolic acid (1), uvaol (2), oleanolic aldehyde (3), and ursolic aldehyde (4), together with two fatty acids, methyl linoleate (5) and ethyl oleate (6). To evaluate the efficacy of promoting osteoblast differentiation and the expression of mRNA biomarkers related to osteogenesis, we tested the isolated compounds in the mouse mesenchymal stem cell line, C3H10T1/2. Alkaline phosphate staining demonstrated that triterpenes (1–4) displayed osteogenic activity. Particularly noteworthy, ursolic aldehyde (4) exhibited the most potent effect, showing an 11.2-fold higher activity at a concentration of 10 μg/mL compared to the negative control. Moreover, ursolic aldehyde (4) upregulated the gene expression of bone formation-related biomarkers, including Runx2, Osterix, Alp, and Osteopontin. These findings suggest that the fruit extract of H. rhamnoides may have potential as a nutraceutical for promoting bone health, with ursolic aldehyde (4) identified as an active constituent.